EVH Stock Recent News

Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens.

Company to Participate in Upcoming Conferences WASHINGTON , April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.

Evolent Health, Inc. (NYSE:EVH ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Charles Rhyee - TD Cowen Andrea Alfonso - UBS Jailendra Singh - Truist Securities Ryan Daniels - William Blair Jeff Garro – Stephens Anne Samuel - J.P. Morgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler David Larsen - BTIG Daniel Grosslight – Citi Matthew Shea - Needham Operator Welcome to the Evolent Earnings Conference Call for the Fourth Quarter and Year End December 31, 2024.

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago.

Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.

Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Richard " Rick "  Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.

DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024.